GE – Portuguese Journal of Gastroenterology

GE Port J Gastroenterol 2023;30:451–454 DOI: 10.1159/000527034 Received: June 14, 2022 Accepted: August 22, 2022 Published online: October 24, 2022

Pancreatic Insulinoma: When Surgery Is Not an Option

Maria Azevedo Silva^a André Ruge^a Nuno Vicente^b Alexandra Fernandes^a Eduardo Pereira^{a, c} Helena Vasconcelos^a

^aDepartment of Gastroenterology, Centro Hospitalar de Leiria, Leiria, Portugal; ^bDepartment of Endocrinology, Centro Hospitalar de Leiria, Leiria, Portugal; ^cDepartment of Gastroenterology, Hospital Amato Lusitano, Castelo Branco, Portugal

Keywords

Insulinoma · Pancreatic neuroendocrine tumor · Endoscopic ultrasonography · Alcohol ablation

Insulinoma Pancreático: Quando a Cirurgia Não é Opção

Palavras Chave Insulinoma · Tumor neuroendócrino pancreático · Ecoendoscopia · Ablação por álcool

A 74-year-old woman, with the history of obesity (body mass index: 38.05 kg/m^2), obesity-hypoventilation syndrome, and hypertension, was referred to endocrinology consultation due to symptomatic recurrent hypoglycemia for 15 years with worsening during the last 4 months. Computed tomography revealed a 2-cm hypervascular pancreatic isthmus mass compatible with a neuroendocrine tumor. Fasting insulin (53 µIU/mL, normal range: 3–25) and C-peptide (5.23 ng/mL, normal range: 0.93–3.73) were elevated during severe hypoglycemia, allowing the diagnosis of insulinoma. Endoscopic ultraso-

Karger@karger.com www.karger.com/pjg © 2022 The Author(s). Published by S. Karger AG, Basel

This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense), applicable to the online version of the article only. Usage and distribution for commercial purposes requires written permission. nography (EUS) was consistent with a neuroendocrine tumor adjacent to the main pancreatic duct (MPD; shown in Fig. 1). GaDOTA-NOC-PET was otherwise unremarkable. Diazoxide was started with inpatient dose titration to 150 mg three times daily (t.i.d.). However, she developed a hyperglycemic hyperosmolar syndrome. A lower dose was restarted (50 mg t.i.d.), but generalized edema developed. Considering these adverse events in a patient unfit for surgery, diazoxide was suspended and EUSguided alcohol ablation (EUS-AA) was performed. Using a linear-array echoendoscope (EG-3270UK Slim Ultrasound Video Endoscope, Pentax, Tokyo, Japan; HI VI-SION Preirus Hitachi Medical Systems, Tokyo, Japan) and a 25-gauge needle (EchoTip, Wilson-Cook, Winston-Salem, NC, USA), a total of 0.9 mL of absolute alcohol (fractions of 0.1 mL, three passes) was injected with partial hyperechoic filling (shown in Fig. 2). Two small hypoechoic areas were left untreated to prevent MPD injury. She experienced incomplete response and underwent a second ablation, 3 months later, with equal injection volume (five passes). Two small MPD-adjacent hypoechoic areas persisted (shown in Fig. 3). Prophylactic rectal indomethacin and intravenous hydration were administered. Prophylactic antibiotics were not used. She

Correspondence to: Maria Azevedo Silva, maria.aams@gmail.com

Karger

∂OPEN ACCESS




Fig. 1. Hypoechoic 18-mm lesion in the pancreatic isthmus, in close proximity to the MPD (arrow, **a**) and to the splenic-mesenteric confluence (arrows, **b**). The lesion is hypervascular (color Doppler, **b**) and reveals a predominantly blue elastography pattern (**c**). These features are compatible with a neuroendocrine tumor.




Fig. 2. First EUS-guided alcohol ablation session. A hyperechoic filling of the tumor is noticed from left to right with remaining hypoechoic areas (right).




Fig. 3. Residual hypervascular lesion at the start of the second EUS-guided alcohol ablation session (color Doppler, left). Hyperechoic tumor filling is shown from left to right.

was discharged after glycemic profile stabilization, 8 and 3 days following the first and second sessions, respectively. No adverse events or further hypoglycemia occurred. Fasting insulin normalized. The patient remains asymptomatic after 6 months. Since symptom relief was the treatment goal and given the very low risk of malignant transformation, no further imaging was performed.

Pancreatic insulinomas are rare tumors with an incidence of 4 cases per million per year [1]. They are more frequent in the pancreatic head and often have indolent courses [2]. Surgery is the treatment of choice [3]. Medical therapy is considered in poor surgical candidates, diazoxide being the most used. However, side effects are frequent and the underlying cause is not addressed [4].

Insulinoma EUS-AA was described in 2006 [5]. Reported cases were systematically reviewed, with a total of five pancreatic neck insulinomas submitted to EUS-AA [2]. The median insulinoma size was lower than ours (13 vs. 18 mm), and still the median alcohol injection volume

Statement of Ethics

Ethical approval was not required for this study in accordance with local/national guidelines. Written informed consent was given by the patient authorizing publication of the case, including images.

was larger (1.55 vs. 0.9 mL, per session). That may be justified by the absence of standardized recommendations and by the MPD proximity in our case, increasing the risk of pancreatitis and alcohol-induced duct stricture [2]. EUS-guided radiofrequency ablation is an alternative to EUS-AA with similar results. However, higher costs and lower availability limit its use. Our case supports previous evidence regarding the role of insulinoma EUS-AA in the absence of surgical indication. Small alcohol volumes with repeated sessions may be effective and safer for MPD-adjacent lesions.

EUS-Guided Insulinoma Ablation

GE Port J Gastroenterol 2023;30:451–454 DOI: 10.1159/000527034

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

References

The authors did not receive financial support.

Author Contributions

M.A.S.: revision of the literature and drafting of the manuscript; A.R.: revision of the literature; N.V.: clinical care; A.F.: clinical care, endoscopic procedure, and critical revision of the article; E.P.: endoscopic procedure; and H.V.: final revision and approval of the article.

Data Availability Statement

All data generated and analyzed are included in this manuscript. Further enquiries can be directed to the corresponding author.

- 1 Service FJ, Mcmahon MM, O'brien PC, Ballard DJ. Functioning insulinoma: incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991 Jul;66(7):711–9.
- 2 El Sayed G, Frim L, Franklin J, McCrudden R, Gordon C, Al-Shamma S, et al. Endoscopic ultrasound-guided ethanol and radiofrequency ablation of pancreatic insulinomas: a systematic literature review. Therap Adv Gastroenterol. 2021 Nov;14:17562848211042171.
- 3 Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020 Jan;49(1):1–33.
- 4 Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997 Oct;73(864):640–1.
- 5 Jürgensen C, Schuppan D, Neser F, Ernstberger J, Junghans U, Stölzel U. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc. 2006 Jun;63(7):1059–62.